HLN$11.2
Chart
Performance
Key Stats
AI HLN Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyHaleon plc exhibits strong fundamental characteristics, including robust profitability and a solid balance sheet, supported by positive but not overwhelming thematic tailwinds. Technical indicators suggest a neutral to slightly bearish short-term outlook, requiring careful entry timing.
Thematic
Haleon operates in the consumer healthcare sector, which benefits from stable demand and demographic trends, but lacks strong disruptive thematic growth drivers. ESG initiatives are present but not industry-leading.
Fundamental
Haleon demonstrates strong profitability and robust cash flow generation. Its balance sheet is stable, with manageable debt. Valuation metrics suggest the stock is reasonably priced given its market position and earnings power.
Technical
Haleon's stock is trading within a range, with its price action currently neutral. Key moving averages are mixed across different timeframes, suggesting a lack of strong directional momentum. Oscillators indicate a mixed signal, leaning towards caution.
| Factor | Score |
|---|---|
| Consumer Healthcare Demand | 75 |
| Brand Strength & Portfolio Diversification | 70 |
| Innovation & Product Development | 60 |
| ESG & Sustainability Focus | 55 |
| Regulatory Landscape (Healthcare) | 65 |
| Factor | Score |
|---|---|
| Valuation | 75 |
| Profitability | 70 |
| Growth | 55 |
| Balance Sheet Health | 70 |
| Cash Flow | 85 |
| Dividend Yield | 80 |
| Factor | Score |
|---|---|
| Trend Analysis | 50 |
| Momentum | 45 |
| Volume Confirmation | 65 |
| Support & Resistance | 65 |
| Short-term Oscillators | 55 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Positive EPS Surprises
The company has exceeded EPS estimates in the last three reported quarters (Q4 2024, Q3 2024, Q2 2024), indicating operational efficiency and better-than-expected profitability.
Improving P/E Ratio
The trailing P/E ratio (23.45) has decreased from the previous year's levels, suggesting the stock may be becoming more attractively valued relative to its earnings.
Bearish Points (7)
High Quarterly P/E Ratio
The most recent quarterly P/E ratio (183.4 for Q4 2024) is significantly elevated compared to the trailing P/E (23.45), indicating potential overvaluation based on short-term earnings.
Revenue Decline in Most Recent Quarter
Revenue in Q4 2024 ($2.759 billion) was lower than Q4 2023 ($2.766 billion), and net income in Q4 2023 was negative (-$3 million), suggesting recent operational challenges.
Calendar
April 2025
25
Ex-Dividend Date
June 2025
5
Next Dividend Date
July 2025
31
Next Earnings Date
H: $
A: $
L: $
H: 2.63B
A: 2.63B
L: 2.63B
Profile
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Aquafresh, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
Seasonals
Price Target
11.97 USD
The 39 analysts offering 1 year price forecasts for HLN have a max estimate of 13.60 and a min estimate of 10.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor; pure-play consumer health spin-off from Johnson & Johnson, mirroring Haleon's market position.
Weight: 90
Major global consumer health company and direct competitor across pain relief, digestive health, and hygiene categories.
Weight: 88
While Kenvue was spun off, J&J remains a significant player in broader healthcare with consumer health legacy and extensive market reach.
Weight: 85
Giant in consumer goods with a strong health and personal care portfolio, including brands like Vicks, Crest, and Oral-B.